Research from the Huber Lab and collaborators across Oxford's Centre for Medicines Discovery (CMD), STRUBI, MRC WIMM and the Dunn School of Pathology laid the scientific foundations for Dark Blue Therapeutics. The company's acquisition by Amgen marks a major milestone in translating Oxford research into potential new therapies for acute leukaemia.

​In an interview with Technology Networks, Prof. Kilian Huber discusses how chemical biology can uncover and validate new therapeutic targets, the role of chemical probes in drug discovery, and the multidisciplinary approaches that drive translational research at Oxford.

Researchers at the University of Oxford identified a previously unknown molecular mechanism that controls the production of DNA building blocks and influences how cancer cells respond to thiopurine therapies. The discovery, published in Science, provides new insights into drug resistance and future therapeutic strategies.

In an interview with WIRED, Prof. Kilian Huber discusses how the Structural Genomics Consortium is transforming drug discovery through open science. By openly sharing chemical probes, biological data and research tools, the initiative brings together academia and industry to accelerate the discovery of new medicines for diseases with unmet clinical need.

Researchers from the Huber Lab at Oxford, working with collaborators at Promega and Stony Brook University, developed the first live-cell biosensor to measure how experimental cancer drugs engage their targets under different metabolic conditions. Published in Nature Communications, the study provides a powerful new tool for precision oncology and advances the development of more selective cancer therapies.

Researchers in the Huber Lab use chemical biology, chemical proteomics and phenotypic screening to uncover new therapeutic targets for cancer and inflammatory diseases. In this Oxford research profile, Prof. Kilian Huber discusses the group's approach to developing chemical probes, validating drug targets and accelerating the translation of fundamental discoveries into future medicines through collaboration and open science.